Alnylam Pharmaceuticals | ALNY - Nettoeinkommen

Aktienkurs
297.72
Täglich Wechseln
-11.77 -3.80%
Monatlich
-6.63%
Jährlich
14.78%
Q2 Prognose
299.00




Nettoeinkommen Veränderung Datum
Acadia Pharmaceuticals USD 273.57M 201.79M 2025-12
Agios Pharmaceuticals USD -99.11M 8.93M 2026-03
Alnylam Pharmaceuticals USD 205.99M 19.57M 2026-03
Amgen USD 1.82B 486M 2026-03
Arrowhead Research USD 30.81M 54.56M 2025-12
BioCryst Pharmaceuticals USD 245.84M 232.95M 2025-12
BioMarin Pharmaceutical USD -46.57M 15.83M 2025-12
Incyte USD 299.28M 124.89M 2025-12
Ionis Pharmaceuticals USD -93M 136M 2026-03
Moderna USD -1.34B 517M 2026-03
Neurocrine Biosciences USD 209.5M 102M 2025-09
Novartis USD 2.41B 1.52B 2025-12
PTC Therapeutics USD -134.96M 150.86M 2025-12
Regeneron Pharmaceuticals USD 727.2M 117.4M 2026-03
Sangamo BioSciences USD -36.13M 12.96M 2024-06
Sanofi EUR -801M 3.6B 2025-12
Sarepta Therapeutics USD -412.23M 232.28M 2025-12
Takeda JPY 103.64B 115.44B 2025-12
Tectonic Therapeutic USD -19.23M 186K 2025-12
Ultragenyx Pharmaceutical USD -129M 51.41M 2025-12
Vertex Pharmaceuticals USD 1.19B 108.2M 2025-12
Xencor USD -6.65M 626K 2025-12